Vaccins prophylactiques antipapillomavirus : enjeux et perspectives

Ferlay, 2004 Beby-Defaux, 2003, Papillomaviridae, 267 Douvier S, Dalac S. -Infections à papillomavirus.- Encycl. Méd. Chir., Maladies infectieuses. 2004;8-054-A-10, 19 p. Hebner, 2006, Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity, Rev. Med. Virol., 16, 83, 10.1002/rmv.488 Dalstein, 2003, Histoire naturelle de l’infection à HPV muqueux, 287 Bozon, 2003, À quel âge les femmes et les hommes commencent-ils leur vie sexuelle ? Comparaison mondiale et évolution récente, Popul. Soc. (Paris), 391, 1 Boulanger, 2004, Épidémiologie de l'infection à HPV, Gynecol. Obstet. Fertil., 32, 218, 10.1016/j.gyobfe.2004.01.013 Bosch, 1995, Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group, J. Natl. Cancer Inst., 87, 796, 10.1093/jnci/87.11.796 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol., 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Bosch, 2002, The causal relation between human papillomavirus and cervical cancer, J. Clin. Pathol., 55, 244, 10.1136/jcp.55.4.244 Bosch, 2003, Épidémiologie des infections à HPV de type muqueux, 335 Schiller, 2004, Human papillomavirus vaccines for cervical cancer prevention. Chapter 45, 1259 Hagensee, 1993, Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins, J. Virol., 67, 315, 10.1128/JVI.67.1.315-322.1993 Rose, 1994, Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera, J. Gen. Virol., 75, 2075, 10.1099/0022-1317-75-8-2075 Munoz, 2004, Against which human papilomavirus types shall we vaccinate and screen? The international perspective, Int. J. Cancer, 111, 278, 10.1002/ijc.20244 Nardelli-Haefliger, 2003, Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 Virus-like particles, J. Natl. Cancer Inst., 95, 1128, 10.1093/jnci/djg018 Mao, 2006, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstet. Gynecol., 107, 18, 10.1097/01.AOG.0000192397.41191.fb Villa, 2005, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol., 6, 271, 10.1016/S1470-2045(05)70101-7 Koff, 2002, Immunogenicity of hepatitis B vaccines: implications of immune memory, Vaccine, 3695, 10.1016/S0264-410X(02)00405-X Munoz, 2006, A review of the phase III clinical data for the quadrivalent human papillomavirus vaccine, Eurogin, 23 Harper, 2006, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet, 367, 1247, 10.1016/S0140-6736(06)68439-0 Combita, 2002, Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses, J. Virol., 76, 6480, 10.1128/JVI.76.13.6480-6486.2002 Mendez, 2005, Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines, J. Infect. Dis., 192, 1158, 10.1086/444391 Taira, 2004, Evaluating human papillomavirus vaccination programs, Emerg. Infect. Dis., 10, 1915, 10.3201/eid1011.040222 Anttila, 2004, Cervical cancer screening programmes and policies in 18 European countries, Br. J. Cancer, 91, 935, 10.1038/sj.bjc.6602069 van Ballegooijen, 2000, Cervical cancer screening in the Netherlands, Eur. J. Cancer, 36, 2244, 10.1016/S0959-8049(00)00317-8 Kyrgiou, 2006, Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis, Lancet, 367, 89, 10.1016/S0140-6736(06)68181-6